{"id":"povidone-iodine-0-3","safety":{"commonSideEffects":[{"rate":null,"effect":"Skin irritation or sensitization"},{"rate":null,"effect":"Allergic contact dermatitis"},{"rate":null,"effect":"Iodine hypersensitivity reactions"},{"rate":null,"effect":"Staining of skin and clothing"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The iodine component penetrates microbial cell walls and oxidizes essential proteins and nucleic acids, leading to rapid cell death. Povidone serves as a carrier that stabilizes the iodine and allows sustained release. This non-selective mechanism makes it effective against a wide range of pathogens, though it does not target specific molecular receptors.","oneSentence":"Povidone-iodine is a broad-spectrum antimicrobial agent that releases iodine to disrupt microbial cell membranes and proteins, killing bacteria, viruses, fungi, and protozoa.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:01:58.832Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Skin antisepsis and wound disinfection"},{"name":"Oral and pharyngeal antisepsis"},{"name":"Vaginal antisepsis"},{"name":"Prevention of infection in minor cuts, scrapes, and burns"}]},"trialDetails":[{"nctId":"NCT05543941","phase":"NA","title":"Evaluating XPERIENCE™ Advanced Surgical Irrigation","status":"RECRUITING","sponsor":"Ottawa Hospital Research Institute","startDate":"2023-04-01","conditions":"Hip Osteoarthritis, Hip Arthritis, Knee Osteoarthritis","enrollment":7600},{"nctId":"NCT06950502","phase":"NA","title":"Comparison of the Effects of Bilateral Transversus Abdominis Plane Block and Bilateral Quadratus Lumborum Block on Postoperative Analgesia in Patients Undergoing Midline Laparotomy","status":"COMPLETED","sponsor":"Ankara University","startDate":"2022-03-01","conditions":"QLB vs TAPB, Quadratus Lumborum Block, Transversus Abdominis Plane (TAP) Block","enrollment":120},{"nctId":"NCT04745663","phase":"PHASE4","title":"Optimizing Preoperative Disinfection of Eyes","status":"TERMINATED","sponsor":"Norwegian University of Science and Technology","startDate":"2021-02-08","conditions":"Eye Infections","enrollment":150},{"nctId":"NCT00961675","phase":"PHASE3","title":"FST-201 in the Treatment of Acute Otitis Externa","status":"COMPLETED","sponsor":"Shire","startDate":"2009-08-31","conditions":"Acute Otitis Externa","enrollment":70},{"nctId":"NCT04767737","phase":"NA","title":"The Effect of Aromatherapy on the Insulin Injection Pain","status":"COMPLETED","sponsor":"Karadeniz Technical University","startDate":"2020-05-01","conditions":"Pain, Aromatherapy, Subcutaneous Injections","enrollment":180},{"nctId":"NCT03062605","phase":"PHASE3","title":"Reducing Bacteria That Cause Tooth Decay","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2011-05-21","conditions":"Caries, Dental, Cariostatic Agents","enrollment":48},{"nctId":"NCT01518842","phase":"NA","title":"Effect of Intravitreal Bone Marrow Stem Cells on Ischemic Retinopathy","status":"UNKNOWN","sponsor":"University of Sao Paulo","startDate":"2011-09","conditions":"Ischemia","enrollment":30},{"nctId":"NCT02223338","phase":"NA","title":"Bacterial Resistance in Patients Receiving Post-Intravitreal Injection Antibiotics","status":"COMPLETED","sponsor":"Loma Linda University","startDate":"2014-10","conditions":"Bacterial Resistance","enrollment":120},{"nctId":"NCT01560715","phase":"PHASE2","title":"Autologous Bone Marrow-Derived Stem Cells Transplantation For Retinitis Pigmentosa","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2011-06","conditions":"Retinitis Pigmentosa","enrollment":50},{"nctId":"NCT01068561","phase":"PHASE1","title":"Autologous Bone Marrow-Derived Stem Cells Transplantation For Retinitis Pigmentosa","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2009-05","conditions":"Retinitis Pigmentosa","enrollment":5}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Povidone-Iodine 0.3%","genericName":"Povidone-Iodine 0.3%","companyName":"Norwegian University of Science and Technology","companyId":"norwegian-university-of-science-and-technology","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Povidone-iodine is a broad-spectrum antimicrobial agent that releases iodine to disrupt microbial cell membranes and proteins, killing bacteria, viruses, fungi, and protozoa. Used for Skin antisepsis and wound disinfection, Oral and pharyngeal antisepsis, Vaginal antisepsis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}